Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 119, Issue 1, Pages 19-26
Publisher
Springer Nature
Online
2018-05-24
DOI
10.1038/s41416-018-0103-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study
- (2018) Mauro Borzio et al. HEPATOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Prognostic Value of Serum AFP, AFP-L3, and GP73 in Monitoring Short-term Treatment Response and Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation
- (2014) Nan-Ya Wang et al. Asian Pacific Journal of Cancer Prevention
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
- (2012) A. Amini et al. CURRENT CANCER DRUG TARGETS
- Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis
- (2012) Khairuddin Memon et al. JOURNAL OF HEPATOLOGY
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
- (2011) Sònia Tugues et al. MOLECULAR ASPECTS OF MEDICINE
- HCC and angiogenesis: possible targets and future directions
- (2011) Andrew X. Zhu et al. Nature Reviews Clinical Oncology
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) S. Jelic et al. ANNALS OF ONCOLOGY
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma
- (2010) Beom Kyung Kim et al. LIVER INTERNATIONAL
- Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival
- (2009) Ahsun Riaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum -Fetoprotein Response as a Surrogate for Clinical Outcome in Patients Receiving Systemic Therapy for Advanced Hepatocellular Carcinoma
- (2009) S. R. Vora et al. ONCOLOGIST
- Diagnosis of hepatocellular carcinoma
- (2009) Asmaa I Gomaa et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: The surgeon's role in survival
- (2008) X.-F. Zhang et al. EJSO
- New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
- (2008) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now